ADORA2A and head and neck squamous cell carcinoma: Preclinical studies in HNSCC mouse models demonstrated that the A2AR antagonist SCH58261 significantly enhances CD8+ T‐cell‐mediated antitumor responses, suggesting the potential of A2AR pathway inhibition to improve immunotherapy efficacy [226].